Bellicum: MD Anderson Acquiring Inducible Switch Technologies: Details

The University of Texas MD Anderson Cancer Center announced it has acquired certain assets from Bellicum Pharmaceuticals related to the CaspaCIDe switch platform and the GoCAR platform. The deal also includes clinical-grade stocks of rimiducid, an agent used to trigger the switches. The post MD Anderson Acquiring Inducible Switch Technologies: Details appeared first on Pulse 2.0.